- Home
- GOVX vs COCP Comparison
GOVX vs COCP Comparison
Compare GOVX & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOVX
- COCP
- Stock Information
- Founded
- GOVX 2001
- COCP 2006
- Country
- GOVX United States
- COCP United States
- Employees
- GOVX N/A
- COCP N/A
- Industry
- GOVX Biotechnology: Pharmaceutical Preparations
- COCP Biotechnology: Pharmaceutical Preparations
- Sector
- GOVX Health Care
- COCP Health Care
- Exchange
- GOVX Nasdaq
- COCP Nasdaq
- Market Cap
- GOVX 16.8M
- COCP 15.4M
- IPO Year
- GOVX N/A
- COCP N/A
- Fundamental
- Price
- GOVX $0.41
- COCP $1.00
- Analyst Decision
- GOVX Strong Buy
- COCP Strong Buy
- Analyst Count
- GOVX 2
- COCP 1
- Target Price
- GOVX $7.00
- COCP $6.00
- AVG Volume (30 Days)
- GOVX 524.6K
- COCP 82.9K
- Earning Date
- GOVX 11-13-2025
- COCP 11-14-2025
- Dividend Yield
- GOVX N/A
- COCP N/A
- EPS Growth
- GOVX N/A
- COCP N/A
- EPS
- GOVX N/A
- COCP N/A
- Revenue
- GOVX $3,353,560.00
- COCP N/A
- Revenue This Year
- GOVX N/A
- COCP N/A
- Revenue Next Year
- GOVX N/A
- COCP N/A
- P/E Ratio
- GOVX N/A
- COCP N/A
- Revenue Growth
- GOVX 8.52
- COCP N/A
- 52 Week Low
- GOVX $0.37
- COCP $0.90
- 52 Week High
- GOVX $3.01
- COCP $3.26
- Technical
- Relative Strength Index (RSI)
- GOVX 35.66
- COCP 46.82
- Support Level
- GOVX $0.37
- COCP $0.90
- Resistance Level
- GOVX $0.44
- COCP $0.96
- Average True Range (ATR)
- GOVX 0.03
- COCP 0.05
- MACD
- GOVX -0.00
- COCP 0.00
- Stochastic Oscillator
- GOVX 26.59
- COCP 51.06
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.
About COCP Cocrystal Pharma Inc.
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).